I-Radiolabeled F56 peptide was designed as a radioactive analogue of F56 (peptide WHSDMEWWYLLG) to bind with VEGFR1 receptor. It was synthesized in high radiochemical yield and specific activity. The stability of I-F56 was tested, and the bioactivity of I-F56 was confirmed by both cell uptake and binding affinity measurement in VEGFR1 positive BGC-823 cells. The time-radioactivity relationship and biodistribution of I-F56 tracer were conducted using nude mice bearing human gastric carcinoma BGC-823, by noninvasive micro-SPECT/CT imaging. The tracer's tumor uptake was further confirmed by autoradiography and HE stain of I-F56 in tumor tissues ex vivo. Those results demonstrated that I-F56 holds great potential as a diagnostic agent in both molecular imaging and radioanalysis probe for gastric cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304288 | PMC |
http://dx.doi.org/10.1021/acsmedchemlett.6b00498 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!